{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:49:59Z","timestamp":1792601399574,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018696","name":"HORIZON EUROPE Health","doi-asserted-by":"publisher","award":["REMEDI4ALL - 101057442"],"award-info":[{"award-number":["REMEDI4ALL - 101057442"]}],"id":[{"id":"10.13039\/100018696","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are no licensed treatments for children with osteogenesis imperfecta. Children currently receive off-label treatment with bisphosphonates, without any consistent approach to dose, drug or route of administration. Meta-analyses suggest that anti-fracture efficacy of such interventions is equivocal. New therapies are undergoing clinical trials, and it is likely that one or more will receive marketing authorisation within the next three to five years. The long-term outcome from such interventions will need to be studied carefully well beyond the period over which the clinical trials are conducted, and a consistent approach to the collection of data in this regard will be needed as a major collaborative effort.<\/jats:p>","DOI":"10.1007\/s00223-024-01202-7","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T19:01:51Z","timestamp":1711738911000},"page":"812-827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Medical Management for Fracture Prevention in Children with Osteogenesis Imperfecta"],"prefix":"10.1007","volume":"115","author":[{"given":"Paul","family":"Arundel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7263-8546","authenticated-orcid":false,"given":"Nick","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"issue":"12","key":"1202_CR1","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1359\/jbmr.040902","volume":"19","author":"C Cooper","year":"2004","unstructured":"Cooper C, Dennison EM, Leufkens HG, Bishop N, van Staa TP (2004) Epidemiology of childhood fractures in Britain: a study using the general practice research database. J Bone Miner Res 19(12):1976\u20131981","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1202_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jpeds.2004.09.029","volume":"146","author":"A Goulding","year":"2005","unstructured":"Goulding A, Jones IE, Williams SM, Grant AM, Taylor RW, Manning PJ, Langley J (2005) First fracture is associated with increased risk of new fractures during growth. J Pediatr 146(2):286\u2013288","journal-title":"J Pediatr"},{"issue":"9","key":"1202_CR3","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1359\/jbmr.060601","volume":"21","author":"EM Clark","year":"2006","unstructured":"Clark EM, Ness AR, Bishop NJ, Tobias JH (2006) Association between bone mass and fractures in children: a prospective cohort study. J Bone Miner Res 21(9):1489\u20131495","journal-title":"J Bone Miner Res"},{"issue":"7","key":"1202_CR4","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1359\/jbmr.080303","volume":"23","author":"EM Clark","year":"2008","unstructured":"Clark EM, Ness AR, Tobias JH (2008) Vigorous physical activity increases fracture risk in children irrespective of bone mass: a prospective study of the independent risk factors for fractures in healthy children. J Bone Miner Res 23(7):1012\u20131022","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1202_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/jbmr.2835","volume":"31","author":"N Bishop","year":"2016","unstructured":"Bishop N (2016) Bone material properties in osteogenesis imperfecta. J Bone Miner Res 31(4):699\u2013708","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1202_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","volume":"26","author":"F Rauch","year":"2000","unstructured":"Rauch F, Travers R, Parfitt AM, Glorieux FH (2000) Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 26(6):581\u2013589","journal-title":"Bone"},{"issue":"4","key":"1202_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11914-996-0025-2","volume":"4","author":"F Rauch","year":"2006","unstructured":"Rauch F, Glorieux FH (2006) Treatment of children with osteogenesis imperfecta. Curr Osteoporos Rep 4(4):159\u2013164","journal-title":"Curr Osteoporos Rep"},{"key":"1202_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-12-54","volume":"12","author":"CL Hill","year":"2014","unstructured":"Hill CL, Baird WO, Walters SJ (2014) Quality of life in children and adolescents with Osteogenesis Imperfecta: a qualitative interview based study. Health Qual Life Outcomes 12:54","journal-title":"Health Qual Life Outcomes"},{"issue":"5 Pt 1","key":"1202_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0022-3476(79)80741-6","volume":"95","author":"S Castells","year":"1979","unstructured":"Castells S, Colbert C, Chakrabarti C, Bachtell RS, Kassner EG, Yasumura S (1979) Therapy of osteogenesis imperfecta with synthetic salmon calcitonin. J Pediatr 95(5 Pt 1):807\u2013811","journal-title":"J Pediatr"},{"issue":"5","key":"1202_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/BF00350961","volume":"16","author":"JP Devogelaer","year":"1987","unstructured":"Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C (1987) Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16(5):360\u2013363","journal-title":"Skeletal Radiol"},{"issue":"1","key":"1202_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/01241398-198801000-00017","volume":"8","author":"JP Huaux","year":"1988","unstructured":"Huaux JP, Lokietek W (1988) Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop 8(1):71\u201372","journal-title":"J Pediatr Orthop"},{"issue":"14","key":"1202_CR12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339(14):947\u2013952","journal-title":"N Engl J Med"},{"issue":"1","key":"1202_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1651-2227.1998.tb01388.x","volume":"87","author":"E Astrom","year":"1998","unstructured":"Astrom E, Soderhall S (1998) Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 87(1):64\u201368","journal-title":"Acta Paediatr"},{"issue":"4","key":"1202_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0022-3476(97)70074-X","volume":"131","author":"B Bembi","year":"1997","unstructured":"Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G (1997) Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131(4):622\u2013625","journal-title":"J Pediatr"},{"issue":"4","key":"1202_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/00005792-199707000-00005","volume":"76","author":"C Brumsen","year":"1997","unstructured":"Brumsen C, Hamdy NA, Papapoulos SE (1997) Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Med (Baltim) 76(4):266\u2013283","journal-title":"Med (Baltim)"},{"issue":"3","key":"1202_CR16","first-page":"261","volume":"157","author":"I Fujiwara","year":"1998","unstructured":"Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A (1998) Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr 157(3):261\u2013262","journal-title":"Eur J Pediatr"},{"issue":"3","key":"1202_CR17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1210\/jc.2002-021371","volume":"88","author":"F Rauch","year":"2003","unstructured":"Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH (2003) Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88(3):986\u2013992","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1202_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1210\/jc.2005-2036","volume":"91","author":"F Rauch","year":"2006","unstructured":"Rauch F, Travers R, Glorieux FH (2006) Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 91(2):511\u2013516","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1202_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1359\/JBMR.041232","volume":"20","author":"D Gatti","year":"2005","unstructured":"Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L et al (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20(5):758\u2013763","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1202_CR20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1136\/adc.2007.125468","volume":"93","author":"S Senthilnathan","year":"2008","unstructured":"Senthilnathan S, Walker E, Bishop NJ (2008) Two doses of pamidronate in infants with osteogenesis imperfecta. Arch Dis Child 93(5):398\u2013400","journal-title":"Arch Dis Child"},{"issue":"5\u20136","key":"1202_CR21","first-page":"485","volume":"25","author":"ER Barros","year":"2012","unstructured":"Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M (2012) Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 25(5\u20136):485\u2013491","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"9419","key":"1202_CR22","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","volume":"363","author":"R Sakkers","year":"2004","unstructured":"Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H et al (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363(9419):1427\u20131431","journal-title":"Lancet"},{"issue":"6","key":"1202_CR23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","volume":"25","author":"MG Seikaly","year":"2005","unstructured":"Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA (2005) Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 25(6):786\u2013791","journal-title":"J Pediatr Orthop"},{"issue":"7","key":"1202_CR24","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1359\/jbmr.090213","volume":"24","author":"F Rauch","year":"2009","unstructured":"Rauch F, Munns CF, Land C, Cheung M, Glorieux FH (2009) Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 24(7):1282\u20131289","journal-title":"J Bone Miner Res"},{"issue":"9902","key":"1202_CR25","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","volume":"382","author":"N Bishop","year":"2013","unstructured":"Bishop N, Adami S, Ahmed SF, Anton J, Arundel P, Burren CP et al (2013) Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 382(9902):1424\u20131432","journal-title":"Lancet"},{"issue":"1","key":"1202_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1359\/jbmr.090712","volume":"25","author":"N Bishop","year":"2010","unstructured":"Bishop N, Harrison R, Ahmed F, Shaw N, Eastell R, Campbell M et al (2010) A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res 25(1):32\u201340","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1202_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1210\/jc.2010-0636","volume":"96","author":"LM Ward","year":"2011","unstructured":"Ward LM, Rauch F, Whyte MP, D\u2019Astous J, Gates PE, Grogan D et al (2011) Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 96(2):355\u2013364","journal-title":"J Clin Endocrinol Metab"},{"key":"1202_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005088.pub3","author":"K Dwan","year":"2014","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D (2014) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD005088.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1202_CR29","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jbmr.2410","volume":"30","author":"JD Hald","year":"2015","unstructured":"Hald JD, Evangelou E, Langdahl BL, Ralston SH (2015) Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res 30(5):929\u2013933","journal-title":"J Bone Miner Res"},{"issue":"12","key":"1202_CR30","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/jbmr.2567","volume":"30","author":"T Palomo","year":"2015","unstructured":"Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, Rauch F (2015) Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res 30(12):2150\u20132157","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1202_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/ijem.ijem_268_22","volume":"27","author":"A Kumar","year":"2023","unstructured":"Kumar A, Saikia UK, Bhuyan AK, Baro A, Prasad SG (2023) Zoledronic acid treatment in infants and toddlers with osteogenesis imperfecta is safe and effective: a tertiary care centre experience. Indian J Endocrinol Metab 27(3):255\u2013259","journal-title":"Indian J Endocrinol Metab"},{"issue":"5","key":"1202_CR32","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s00330-016-4556-3","volume":"27","author":"E Adiotomre","year":"2017","unstructured":"Adiotomre E, Summers L, Allison A, Walters SJ, Digby M, Broadley P et al (2017) Diagnostic accuracy of DXA compared to conventional spine radiographs for the detection of vertebral fractures in children. Eur Radiol 27(5):2188\u20132199","journal-title":"Eur Radiol"},{"key":"1202_CR33","doi-asserted-by":"publisher","first-page":"115249","DOI":"10.1016\/j.bone.2020.115249","volume":"133","author":"FF Alqahtani","year":"2020","unstructured":"Alqahtani FF, Crabtree NJ, Bromiley PA, Cootes T, Broadley P, Lang I, Offiah AC (2020) Diagnostic performance of morphometric vertebral fracture analysis (MXA) in children using a 33-point software program. Bone 133:115249","journal-title":"Bone"},{"key":"1202_CR34","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.bonr.2021.101102","volume":"15","author":"EH Campanini","year":"2021","unstructured":"Campanini EH, Baker D, Arundel P, Bishop NJ, Offiah AC, Keigwin S et al (2021) High bone mass phenotype in a cohort of patients with Osteogenesis Imperfecta caused due to BMP1 and C-propeptide cleavage variants in COL1A1. Bone Rep 15:101102","journal-title":"Bone Rep"},{"issue":"3","key":"1202_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000369582","volume":"83","author":"A Biggin","year":"2015","unstructured":"Biggin A, Zheng L, Briody JN, Coorey CP, Munns CF (2015) The long-term effects of switching from active intravenous bisphosphonate treatment to low-dose maintenance therapy in children with osteogenesis imperfecta. Horm res paediatr 83(3):183\u2013189","journal-title":"Horm res paediatr"},{"issue":"12","key":"1202_CR36","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1002\/jbmr.3833","volume":"34","author":"ME Robinson","year":"2019","unstructured":"Robinson ME, Trejo P, Palomo T, Glorieux FH, Rauch F (2019) Osteogenesis imperfecta: skeletal outcomes after bisphosphonate discontinuation at final height. J Bone Miner Res 34(12):2198\u20132204","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1202_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s11914-020-00621-3","volume":"18","author":"MR Celin","year":"2020","unstructured":"Celin MR, Simon JC, Krzak JJ, Fial AV, Kruger KM, Smith PA, Harris GF (2020) Do bisphosphonates alleviate pain in children? A systematic review. Curr Osteoporos Rep 18(5):486\u2013504","journal-title":"Curr Osteoporos Rep"},{"issue":"4","key":"1202_CR38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.bone.2006.11.020","volume":"40","author":"F Rauch","year":"2007","unstructured":"Rauch F, Cornibert S, Cheung M, Glorieux FH (2007) Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40(4):821\u2013827","journal-title":"Bone"},{"key":"1202_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bone.2016.02.018","volume":"86","author":"A Sato","year":"2016","unstructured":"Sato A, Ouellet J, Muneta T, Glorieux FH, Rauch F (2016) Scoliosis in osteogenesis imperfecta caused by COL1A1\/COL1A2 mutations\u2014genotype-phenotype correlations and effect of bisphosphonate treatment. Bone 86:53\u201357","journal-title":"Bone"},{"issue":"5","key":"1202_CR40","doi-asserted-by":"publisher","first-page":"e10118","DOI":"10.1002\/jbm4.10118","volume":"3","author":"JS Bains","year":"2019","unstructured":"Bains JS, Carter EM, Citron KP, Boskey AL, Shapiro JR, Steiner RD et al (2019) A Multicenter observational cohort study to evaluate the effects of bisphosphonate exposure on bone mineral density and other health outcomes in osteogenesis imperfecta. JBMR Plus 3(5):e10118","journal-title":"JBMR Plus"},{"issue":"5 Pt 1","key":"1202_CR41","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1542\/peds.111.5.1030","volume":"111","author":"L Zeitlin","year":"2003","unstructured":"Zeitlin L, Rauch F, Plotkin H, Glorieux FH (2003) Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111(5 Pt 1):1030\u20131036","journal-title":"Pediatrics"},{"key":"1202_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/JMDH.S113483","volume":"10","author":"C Marr","year":"2017","unstructured":"Marr C, Seasman A, Bishop N (2017) Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. J Multidiscip Healthc 10:145\u2013155","journal-title":"J Multidiscip Healthc"},{"issue":"5","key":"1202_CR43","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/cts.12783","volume":"13","author":"L Zhytnik","year":"2020","unstructured":"Zhytnik L, Maasalu K, Reimand T, Duy BH, Koks S, Martson A (2020) Inter-and Intrafamilial phenotypic variability in individuals with collagen-related osteogenesis imperfecta. Clin Transl Sci 13(5):960\u2013971","journal-title":"Clin Transl Sci"},{"issue":"3","key":"1202_CR44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3171\/2014.11.PEDS14113","volume":"15","author":"H Arponen","year":"2015","unstructured":"Arponen H, Vuorimies I, Haukka J, Valta H, Waltimo-Siren J, Makitie O (2015) Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates. J Neurosurg Pediatr 15(3):313\u2013320","journal-title":"J Neurosurg Pediatr"},{"issue":"5","key":"1202_CR45","first-page":"1846","volume":"85","author":"H Plotkin","year":"2000","unstructured":"Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85(5):1846\u20131850","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1202_CR46","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1210\/jc.2015-2680","volume":"100","author":"S George","year":"2015","unstructured":"George S, Weber DR, Kaplan P, Hummel K, Monk HM, Levine MA (2015) Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience. J Clin Endocrinol Metab 100(11):4163\u20134171","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1202_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.bone.2004.03.008","volume":"35","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Mier RJ, Glorieux FH (2004) Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 35(1):231\u2013234","journal-title":"Bone"},{"issue":"11","key":"1202_CR48","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1359\/JBMR.040814","volume":"19","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH (2004) Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 19(11):1779\u20131786","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1202_CR49","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.injury.2021.01.007","volume":"52","author":"I Pountos","year":"2021","unstructured":"Pountos I, Panteli M, Walters G, Giannoudis PV (2021) NSAIDs inhibit bone healing through the downregulation of TGF-beta3 expression during endochondral ossification. Injury 52(6):1294\u20131299","journal-title":"Injury"},{"issue":"2","key":"1202_CR50","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00223-019-00615-z","volume":"106","author":"A Morse","year":"2020","unstructured":"Morse A, McDonald MM, Mikulec K, Schindeler A, Munns CF, Little DG (2020) Pretreatment with pamidronate decreases bone formation but increases callus bone volume in a rat closed fracture model. Calcif Tissue Int 106(2):172\u2013179","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"1202_CR51","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1056\/NEJMoa023110","volume":"349","author":"MP Whyte","year":"2003","unstructured":"Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349(5):457\u2013463","journal-title":"N Engl J Med"},{"key":"1202_CR52","doi-asserted-by":"publisher","first-page":"116788","DOI":"10.1016\/j.bone.2023.116788","volume":"173","author":"MP Whyte","year":"2023","unstructured":"Whyte MP, McAlister WH, Dhiman V, Gopinathan NR, Bhadada SK (2023) Drug-induced osteopetrosis. Bone 173:116788","journal-title":"Bone"},{"issue":"3","key":"1202_CR53","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1359\/JBMR.051207","volume":"21","author":"C Land","year":"2006","unstructured":"Land C, Rauch F, Glorieux FH (2006) Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 21(3):374\u2013379","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1202_CR54","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/jbmr.3071","volume":"32","author":"P Trejo","year":"2017","unstructured":"Trejo P, Fassier F, Glorieux FH, Rauch F (2017) Diaphyseal femur fractures in osteogenesis imperfecta: characteristics and relationship with bisphosphonate treatment. J Bone Miner Res 32(5):1034\u20131039","journal-title":"J Bone Miner Res"},{"issue":"7","key":"1202_CR55","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/jbmr.2805","volume":"31","author":"RF Vasanwala","year":"2016","unstructured":"Vasanwala RF, Sanghrajka A, Bishop NJ, Hogler W (2016) Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: are we overtreating? J Bone Miner Res 31(7):1449\u20131454","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1202_CR56","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s002239900600","volume":"64","author":"A Boyde","year":"1999","unstructured":"Boyde A, Travers R, Glorieux FH, Jones SJ (1999) The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif Tissue Int 64(3):185\u2013190","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"1202_CR57","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00223-020-00707-1","volume":"107","author":"B Malmgren","year":"2020","unstructured":"Malmgren B, Tsilingaridis G, Monsef-Johansson N, Qahtani ZHA, Dahllof G, Astrom E (2020) Bisphosphonate therapy and tooth development in children and adolescents with osteogenesis imperfecta. Calcif Tissue Int 107(2):143\u2013150","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"1202_CR58","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1749-4486.2012.02476.x","volume":"37","author":"TH Ting","year":"2012","unstructured":"Ting TH, Zacharin MR (2012) Hearing in bisphosphonate-treated children with osteogenesis imperfecta: our experience in thirty six young patients. Clin Otolaryngol 37(3):229\u2013233","journal-title":"Clin Otolaryngol"},{"issue":"3","key":"1202_CR59","doi-asserted-by":"publisher","first-page":"e10592","DOI":"10.1002\/jbm4.10592","volume":"6","author":"S Sithambaran","year":"2022","unstructured":"Sithambaran S, Harrison R, Gopal-Kothandapandi S, Rigby A, Bishop N (2022) Bisphosphonate treatment alters the skeletal response to mechanical stimulation in children with osteogenesis imperfecta: a pilot study. JBMR Plus 6(3):e10592","journal-title":"JBMR Plus"},{"issue":"3","key":"1202_CR60","first-page":"183","volume":"12","author":"O Semler","year":"2012","unstructured":"Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E (2012) First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 12(3):183\u2013188","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"1202_CR61","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","volume":"9","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn H, Netzer C, Koerber F, Schoenau E, Semler O (2014) Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis 9:145","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1202_CR62","first-page":"24","volume":"16","author":"H Hoyer-Kuhn","year":"2016","unstructured":"Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P et al (2016) Safety and efficacy of denosumab in children with osteogenesis imperfect\u2013a first prospective trial. J Musculoskelet Neuronal Interact 16(1):24\u201332","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"1","key":"1202_CR63","first-page":"76","volume":"18","author":"P Trejo","year":"2018","unstructured":"Trejo P, Rauch F, Ward L (2018) Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 18(1):76\u201380","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"2","key":"1202_CR64","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI71101","volume":"124","author":"ES Orwoll","year":"2014","unstructured":"Orwoll ES, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C et al (2014) Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 124(2):491\u2013498","journal-title":"J Clin Invest"},{"key":"1202_CR65","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152571","author":"IW Song","year":"2022","unstructured":"Song IW, Nagamani SC, Nguyen D, Grafe I, Sutton VR, Gannon FH et al (2022) Targeting TGF-beta for treatment of osteogenesis imperfecta. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI152571","journal-title":"J Clin Invest"},{"issue":"242","key":"1202_CR66","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/adc.45.242.581","volume":"45","author":"JA Kuzemko","year":"1970","unstructured":"Kuzemko JA (1970) Osteogenesis imperfecta tarda treated with sodium fluoride. Arch Dis Child 45(242):581\u2013582","journal-title":"Arch Dis Child"},{"issue":"3","key":"1202_CR67","first-page":"151","volume":"24","author":"N Bilginturan","year":"1982","unstructured":"Bilginturan N, Ozsoylu S, Yordam N (1982) Further experiences with sodium fluoride treatment in osteogenesis imperfecta. Turk J Pediatr 24(3):151\u2013157","journal-title":"Turk J Pediatr"},{"issue":"2","key":"1202_CR68","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1359\/jbmr.2003.18.2.237","volume":"18","author":"JC Marini","year":"2003","unstructured":"Marini JC, Hopkins E, Glorieux FH, Chrousos GP, Reynolds JC, Gundberg CM, Reing CM (2003) Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res 18(2):237\u2013243","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1202_CR69","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0022-3476(96)70077-X","volume":"129","author":"F Antoniazzi","year":"1996","unstructured":"Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S, Zamboni G et al (1996) Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 129(3):432\u2013439","journal-title":"J Pediatr"},{"issue":"8","key":"1202_CR70","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1359\/jbmr.070418","volume":"22","author":"MS Cheung","year":"2007","unstructured":"Cheung MS, Glorieux FH, Rauch F (2007) Natural history of hyperplastic callus formation in osteogenesis imperfecta type V. J Bone Miner Res 22(8):1181\u20131186","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1202_CR71","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1097\/BPO.0000000000002524","volume":"44","author":"V Eaton","year":"2024","unstructured":"Eaton V, Braaten M, Schissel M, Wallace M (2024) Assessing the safety and efficacy of tranexamic acid usage in osteogenesis imperfecta patients. J Pediatr Orthop 44(1):e73\u2013e78","journal-title":"J Pediatr Orthop"},{"issue":"4","key":"1202_CR72","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1086\/383252","volume":"74","author":"WA Cabral","year":"2004","unstructured":"Cabral WA, Marini JC (2004) High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta. Am J Hum Genet 74(4):752\u2013760","journal-title":"Am J Hum Genet"},{"issue":"3","key":"1202_CR73","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/6529","volume":"5","author":"EM Horwitz","year":"1999","unstructured":"Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M et al (1999) Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5(3):309\u2013313","journal-title":"Nat Med"},{"issue":"13","key":"1202_CR74","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1073\/pnas.132252399","volume":"99","author":"EM Horwitz","year":"2002","unstructured":"Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY et al (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 99(13):8932\u20138937","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1202_CR75","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5966\/sctm.2013-0090","volume":"3","author":"C Gotherstrom","year":"2014","unstructured":"Gotherstrom C, Westgren M, Shaw SW, Astrom E, Biswas A, Byers PH et al (2014) Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cells Transl Med 3(2):255\u2013264","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"1202_CR76","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1002\/ctm2.265","volume":"11","author":"A Infante","year":"2021","unstructured":"Infante A, Gener B, Vazquez M, Olivares N, Arrieta A, Grau G et al (2021) Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro-osteogenic paracrine response: TERCELOI clinical trial. Clin Transl Med 11(1):e265","journal-title":"Clin Transl Med"},{"issue":"10","key":"1202_CR77","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1002\/jbmr.3473","volume":"33","author":"Y Jeong","year":"2018","unstructured":"Jeong Y, Daghlas SA, Xie Y, Hulbert MA, Pfeiffer FM, Dallas MR et al (2018) Skeletal response to soluble activin receptor type IIB in mouse models of osteogenesis imperfecta. J Bone Miner Res 33(10):1760\u20131772","journal-title":"J Bone Miner Res"},{"issue":"7","key":"1202_CR78","doi-asserted-by":"publisher","first-page":"e10753","DOI":"10.1002\/jbm4.10753","volume":"7","author":"CL Omosule","year":"2023","unstructured":"Omosule CL, Joseph D, Weiler B, Gremminger VL, Silvey S, Lafaver BN et al (2023) Whole-body metabolism and the musculoskeletal impacts of targeting activin a and myostatin in severe osteogenesis imperfecta. JBMR Plus 7(7):e10753","journal-title":"JBMR Plus"},{"key":"1202_CR79","doi-asserted-by":"publisher","first-page":"115867","DOI":"10.1016\/j.bone.2021.115867","volume":"145","author":"I Boraschi-Diaz","year":"2021","unstructured":"Boraschi-Diaz I, Chen G, Polak-Nachumow J, Young RN, Rauch F (2021) Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta. Bone 145:115867","journal-title":"Bone"},{"issue":"5Pt A","key":"1202_CR80","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.bbadis.2018.02.002","volume":"1864","author":"R Besio","year":"2018","unstructured":"Besio R, Iula G, Garibaldi N, Cipolla L, Sabbioneda S, Biggiogera M et al (2018) 4-PBA ameliorates cellular homeostasis in fibroblasts from osteogenesis imperfecta patients by enhancing autophagy and stimulating protein secretion. Biochim Biophys Acta Mol Basis Dis 1864(5Pt A):1642\u20131652","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"6","key":"1202_CR81","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1359\/JBMR.050109","volume":"20","author":"AD Letocha","year":"2005","unstructured":"Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ et al (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20(6):977\u2013986","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1202_CR82","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1359\/JBMR.051006","volume":"21","author":"LA DiMeglio","year":"2006","unstructured":"DiMeglio LA, Peacock M (2006) Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 21(1):132\u2013140","journal-title":"J Bone Miner Res"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01202-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-024-01202-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01202-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T14:02:49Z","timestamp":1732888969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-024-01202-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":82,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1007\/s00223-024-01202-7","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}